key: cord-0918305-059v15xe
authors: Suryadevara, Naveenchandra; Shrihari, Swathi; Gilchuk, Pavlo; VanBlargan, Laura A.; Binshtein, Elad; Zost, Seth J.; Nargi, Rachel S.; Sutton, Rachel E.; Winkler, Emma S.; Chen, Elaine C.; Fouch, Mallorie E.; Davidson, Edgar; Doranz, Benjamin J.; Carnahan, Robert H.; Thackray, Larissa B.; Diamond, Michael S.; Crowe, James E.
title: Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
date: 2021-01-20
journal: bioRxiv
DOI: 10.1101/2021.01.19.427324
sha: 24b099b9ef994be7a6343ad55c8ea11351f80ef7
doc_id: 918305
cord_uid: 059v15xe

Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike (S) protein receptor-binding domain and block virus interactions with the cellular receptor angiotensin-converting enzyme 2. We describe a panel of human mAbs binding to diverse epitopes on the N-terminal domain (NTD) of S protein from SARS-CoV-2 convalescent donors and found a minority of these possessed neutralizing activity. Two mAbs (COV2-2676 and COV2-2489) inhibited infection of authentic SARS-CoV-2 and recombinant VSV/SARS-CoV-2 viruses. We mapped their binding epitopes by alanine-scanning mutagenesis and selection of functional SARS-CoV-2 S neutralization escape variants. Mechanistic studies showed that these antibodies neutralize in part by inhibiting a post-attachment step in the infection cycle. COV2-2676 and COV2-2489 offered protection either as prophylaxis or therapy, and Fc effector functions were required for optimal protection. Thus, natural infection induces a subset of potent NTD-specific mAbs that leverage neutralizing and Fc-mediated activities to protect against SARS-CoV-2 infection using multiple functional attributes.

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 43 as a major threat to global public health, many studies have focused efforts on discovery of potent The heavy chain of the antibodies interact with the N3 and N5 loops of NTD (Fig S2) . This 125 revealed a distinct site of vulnerability on NTD region of spike protein for human neutralizing 126 mAbs and suggested a convergent responses in SARS-CoV-2 immune individuals. 127

We next defined the antibody epitopes at the amino acid level using two complementary 128 methods: alanine-scanning loss-of-binding experiments in cell-surface antigen display and 129 selection of virus escape mutants followed by sequence analysis. Screening of the NTD Ala-scan 130 library identified residues A123, G142, Y144, F157 and N164 as important for binding of COV2-131 2489, and Y144 for binding of mAb COV2-2676. None of these single-residue alanine mutants 132 affected binding of the control NTD-reactive mAb COV2-2305, likely due to the location of key 133 contact residues in the N3 and N5 loops of NTD (Fig 2B and S3A) . 134

To identify neutralization escape mutations, we used a high-throughput RTCA assay as 135 previously described (Gilchuk et al., 2020a; Gilchuk et al., 2020b). We selected viral variants that 136 escape antibody neutralization at a single saturating concentration of 5 μg/mL (COV2-2676) or 50 137 μg/mL (COV2-2489) and identified point mutations. The mutations were F140S (orange) for 138 COV2-2676, and G142D and R158S (green) for COV2-2489 (Fig 2C) . We confirmed that the 139 mutations in the viral variants we selected in the RTCA assay experiments above conferred 140 resistance to 10 or 100 μg/mL of the rescpetive mAbs (Fig S3B) . The location of the escape 141 mutations was in the same region identified by the alanine-scanning method, although the specific 142 amino acids differed between the two methods. Thus, the two neutralizing NTD antibodies bind 143 to a common antigenic site, but the fine specificity of the epitopes differ. 144

show cell-type specific neutralization, and inhibit at a post-attachment step. We evaluated the 146 ability of mAbs targeting the NTD to bind to the surface of SARS-CoV-2-infected cells since this 147 loss and viral burden, as well as greater lung inflammation and pathology were observed in animals 240 pre-treated with COV2-2676 LALA-PG Fc or COV2-2489 LALA-PG Fc variant IgGs compared 241 to the intact parental mAbs (Fig 4A, B, E, G, and H) . This pattern also was seen with therapy 242 initiated one day after SARS-CoV-2 infection using COV2-2676 LALA-PG Fc or COV2-2489 243 LALA-PG Fc variants (Fig 5A-D) . Overall, these findings suggest that Fc effector function 244 activities contribute to the protection conferred by each of the NTD mAbs. 245

The combination of an RBD-specific neutralizing mAb and an NTD mAb in a cocktail 246 would confer equivalent or better levels of protection, since binding to distinct antigenic sites 247 might mitigate the risk of selection of antibody escape variants. Thus, mAb cocktails that include 248 components binding to different epitopes on S protein offer higher resistance to escape mutations 249 described here (COV2-2676 and COV2-2489). As expected, NTD-reactive mAbs neutralized the 254 RBD mAb escape mutant viruses, and RBD-reactive mAbs neutralized the NTD mAb escape 255 mutant viruses (Fig 6A) . 256 We next treated mice two days after inoculation with SARS-CoV-2 with individual mAbs 257 or a combination of COV2-2381 (RBD-specific) and COV2-2676 (NTD-specific) mAbs. Mice 258 treated with 200 g of COV2-2676, COV2-2489 or COV2-2831 two days after SARS-CoV-2 259 inoculation showed weight loss, viral burden, and inflammatory mediator profiles that were similar 260 to DENV-2D22-treated mice (Fig 6B-D) , consistent with a limited therapeutic window for 261 effective treatment in this stringent transgenic hACE2 mouse model. While mice were not 13 protected from the initial phase of weight loss, viral infection in the lower respiratory tract or heart, 263 or lung inflammation (Fig 6B-D, S5C) , treatment with mAb monotherapy or the cocktail resulted 264 in weight gain beginning approximately one week after infection and survival through two weeks 265 after infection, and this recovery was associated with decreased nasal wash titers and reduced lung 266 pathology (Fig 6B-D) . In comparison, all mice treated with the isotype control mAb DENV-2D22 267 had severe lung pathology and succumbed to infection between eight and nine days after 268 inoculation. These results suggested that diversification of neutralizing antibody responses after 269 natural infection or vaccination (e.g., targeting of vulnerable RBD and NTD sites of the spike) 270 could be beneficial for protective immunity, with a potential implication for therapeutic cocktail 271 warranted. In a large (n =389) panel of mAbs we isolated with reactivity to the SARS-CoV-2 S 280 protein, the majority of mAbs bound to S protein but not to the RBD (Zost et al., 2020b) . We found 281 that a small subset of non-RBD antibodies that recognized the NTD could neutralize SARS-CoV-282 2 infection and confer protection in a stringent hACE2 transgenic mouse model of disease. 283

Our studies highlight the promising functional activities of NTD-specific mAbs. Although 284 these mAbs did not bind as avidly to recombinant S6Pecto protein as did the most potent RBD-285 reactive mAbs we isolated, they neutralized SARS-CoV-2 with potencies comparable to many 286 RBD-targeting antibodies (Zost et CoV, structural studies presented showed that the MERS-CoV mAb 7D10 could bind to the NTD 307 of S protein of MERS-CoV and inhibit RBD-DPP4 interaction through its light chain, which was 308 close to the RBD (Zhou et al., 2019) . We tested that model here but found that neither COV2-2676 309 nor COV2-2489 blocked ACE2 interaction with RBD in soluble protein or in cell-surface-display 310 assays. Antibody fragment studies using Fab, F(ab)2 and IgG forms of COV2-2676 and COV2-311 2489 showed that the Fab forms lost neutralizing activity, possibly suggesting some blocking 312 occurs indirectly by steric effects of the projecting Fc region into the direction of the RBD as in 313 the case for the MERS-CoV mAB 7D10 (Zhou et al., 2019) . However, we did not obtain direct 314 evidence for this mechanism. In cells expressing high hACE2 levels, anti-RBD antibodies partially 315 inhibited attachment of virus, but anti-NTD antibodies did not. 316

To define the fine specificity of this protective epitope, we performed saturation alanine-317 scanning mutagenesis studies and identified critical residues for binding of COV2-2676 or COV2-16 2489 mAbs in the NTD. We showed that SARS- CoV-2 S protein variants with mutations at F140S  319   and G142D, or R158S in the NTD conferred resistance to COV2-2676 or COV2-2489,  320 respectively, using a chimeric replication-competent VSV expressing the SARS-CoV-2 S protein. 321 Consistent with these data, Weisblum et al. identified an NTD epitope (residues 148 to 151), and 322 mutations in this epitope enabled escape from neutralizing antibody activity in a donor plasma 323 specimen (Weisblum et al., 2020) . 324

We first tested the prophylactic efficacy of COV2-2676 or COV2-2489 in a well-defined 325 model of SARS-CoV-2 infection in hACE2-expressing transgenic mice (Winkler et al., 2020) . 326

Mice pre-treated with COV2-2676 or COV2-2489 mAbs exhibited substantially lower viral titers 327 than mice treated with an isotype-control mAb and offered complete protection against death in 328 this model. We also assessed the therapeutic potential of these mAbs in the same mouse model. compared between all groups for two independent experiments (n = 6 for each experimental 479 group; one-way ANOVA with Tukey's post hoc test: ns, not significant, * p < 0.05, * * p < 0.01, 480 * * * p < 0.001, * * * * p < 0.0001). Dashed line represents limit of detection of assay. compared between all groups for two independent experiments (n = 6 to 7 for each 518 experimental group; one-way ANOVA with Tukey's post hoc test: ns, not significant, * p < 519 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001). 520 C. Heat map of cytokine and chemokine levels in lung homogenates harvested in B as measured 521 by a multiplex platform. Log2 fold change compared to lungs from mock-infected animals was 522 plotted in the corresponding heat map (associated statistics are reported in Fig S6B) . 15 μg/mL was applied to a glow-discharged grid with continuous carbon film on 400 square mesh 761 copper electron microscopy grids (Electron Microscopy Sciences). The grids were stained with 762 0.75% uranyl formate (Ohi et al., 2004) . Images were recorded on a Gatan US4000 4k × 4k CCD 763 camera using an FEI TF20 (TFS) transmission electron microscope operated at 200 keV and 764 control with Serial EM. All images were taken at 50,000× magnification with a pixel size of 2.18 765 Å per pixel in low-dose mode at a defocus of 1.5 to 1.8 μm. The total dose for the micrographs 766 was around 30e− per Å2. Image processing was performed using the cryoSPARC software 767 package. Images were imported, CTF-estimated and particles were picked. The particles were 768 extracted with a box size of 256 pixels and binned to 128 pixels. 2D class averages were performed 769 and good classes selected for ab initio model and refinement without symmetry. Model docking 770 to the EM map was done in Chimera (Pettersen et al., 2004) . For SARS-CoV-2 S6Pecto protein, the 771 closed model (PDB:7JJI) was used and PDB:12E8 was used for the Fab (see also Table S2 for 772 details). 773 774 Epitope mapping of antibodies by alanine-scanning mutagenesis. Epitope mapping was 775 performed essentially as described previously (Davidson and Doranz, 2014) using a SARS-CoV-776 2 (strain Wuhan-Hu-1) spike protein NTD shotgun mutagenesis mutation library, made using a 777 full-length expression construct for spike protein, where 215 residues of the NTD (between spike 778 residues 9 and 310) were mutated individually to alanine, and alanine residues to serine. post hoc test using Prism v.9.0 (GraphPad). Viral burden and gene-expression measurements were 897 compared to each other or the isotype control using a one-way ANOVA with Tukey's or Dunnett's 898 post hoc test, respectively, using Prism v.9.0 (GraphPad). Survival curves were estimated using 899 Figure 5C 

Natural deletions in the SARS-CoV-2 spike glycoprotein drive 1083 antibody escape

Enhancing dengue virus maturation using a stable furin over-expressing cell line

Phase I/II study of COVID-19 RNA vaccine 1091 BNT162b1 in adults

Negative Staining and Image Classification -1094

Powerful Tools in Modern Electron Microscopy

Lethality of SARS-CoV-2 1098 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

UCSF Chimera--a visualization system for exploratory research and 1108 analysis

Mapping neutralizing and 1112 immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided 1113 high-resolution serology

Cross-neutralization of SARS-CoV-2 by a 1117 human monoclonal SARS-CoV antibody

Spike mutation D614G alters SARS-CoV-2 1121 fitness

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist 1125 genomic epidemiology

Convergent antibody responses to SARS

CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and 1133 protection from disease in a small animal model

Antibody potency, effector function, 1137 and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Analysis of a SARS-CoV-2-infected 1142 individual reveals development of potent neutralizing antibodies with limited somatic mutation

Landscape and selection of vaccine epitopes in SARS-CoV-1147 2

Prospective mapping of viral mutations that escape antibodies used 1151 to treat COVID-19. bioRxiv

Emergence and rapid spread of a new severe 1155 acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike 1156 mutations in South Africa. medRxiv

Human monoclonal antibody 1160 combination against SARS coronavirus: synergy and coverage of escape mutants

Prevalent, protective, and convergent IgG 1165 recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma

A human monoclonal antibody 1170 blocking SARS-CoV-2 infection

Broad neutralization of SARS-related viruses 1174 by human monoclonal antibodies

Escape from neutralizing 1178 antibodies by SARS-CoV-2 spike protein variants

The IgG Fc 1181 contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc 1182 gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein

SARS-CoV-2 infection of human ACE2-transgenic mice 1187 causes severe lung inflammation and impaired function

Cryo-EM structure of the 2019-nCoV spike in the prefusion 1191 conformation

An alternative binding mode of

antibodies to the SARS-CoV-2 receptor binding domain

DNA vaccine protection against SARS

CoV-2 in rhesus macaques

A proof of concept for neutralizing antibody-guided vaccine 1203 design against SARS-CoV-2. bioRxiv

Potently neutralizing and protective human 1211 antibodies against SARS-CoV-2

Rapid isolation and profiling of a diverse panel of 1215 human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Cytokine and chemokine levels in the lungs of SARS-CoV-2 infected mice

Cytokine and chemokine levels in the lungs of SARS-CoV-2 infected mice at 7 dpi following d-1 treatment with isotype, COV2-2381, COV2-2676, and COV2-2676 LALA PG as measured by a multiplex platform (two independent experiments, n = 6 per group. One-way ANOVA with Tukey's post hoc test: ns, not significant

Cytokine and chemokine levels in the lungs of SARS-CoV-2 infected mice at 7 dpi following d+1 treatment with isotype, COV2-2381, COV2-2676, and COV2-2676 LALA PG as measured by a multiplex platform (two independent experiments, n = 6 per group. One-way ANOVA with Tukey's post hoc test: ns, not significant

Cytokine and chemokine levels in the lungs of SARS-CoV-2 infected mice at 7 dpi following d+1 treatment with isotype, COV2-2381, COV2-2676, and COV2-2676 LALA PG as measured by a multiplex platform (two independent experiments, n = 6 per group. One-way ANOVA with Tukey's post hoc test: ns, not significant